Retreatment of chronic hepatitis C with interferon alpha and ribavirin in non-responders to interferon alpha monotherapy - Analysis of the own experience and review of the literature;Ist eine kombinationstherapie der chronischen hepatitis C mit interferon alpha und ribavirin bei primaren interferon-nonrespondern indiziert? - Eine analyse der eigenen erfahrungen und eine zusammenfassung der literatur

Zeitschrift fur Gastroenterologie

Volumn 36, Issue 9, 1998, Pages 819-827

  Wedemeyer, H ^a   Jackel E ^a   Wedmeyer, J ^a   Frank, H ^a   Schuler A ^a   Trautwein, Chr ^a   Manns, Michael Peter ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hepatitis C; Interferon; Non response; Review; Ribavirin; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; RETREATMENT;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0031662620     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349 (9055): 825-32
2. Seeff LB, Natural history of hepatitis C. Hepatology 1997; 26 (3 suppl. 1): 21S-28S
3. Di Bisceglie AM, Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (3 suppl. 1): 34S-38S
4. Lindsay KL, Therapy of hepatitis C: Overview. Hepatology 1997; 26 (3 suppl. 1): 71S-77S
5. Böker KH, Manns MP. Was bringt die Interferon-therapie bei der chronischen Hepatitis? Internist 1997; 38 (12): 1191-203
6. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of Interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351 (9096): 83-7
7. Davis GL, Esteban R, Rustgi V et al. Retreatment of relapse after Interferon therapy for chronic hepatitis C: An international randomized controlled trial of interferon plus ribavirin vs Interferon alone. [Abstract] Hepatology 1997; 26 (suppl. 2): 247A
8. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995; 46 (1): 43-7
9. Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26 (5): 961-6
10. Bellobuono A, Mondazzi L, Tempini S et al. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: A randomized clinical trial. J Viral Hepat 1997; 4 (3): 185-91
11. Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol 1996; 28 (9): 505-11
12. Salmcron J, Perez-Ruiz M, Ruiz-Extremera A et al. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial. [Abstract] Hepatology 1996; 24 (suppl. 1): 357A
13. Andreone P, Cursaro C, Gramenzi A et al. IFN alpha-n3 vs IFN alpha-n3 plus ribavirin in chronic hepatitis G resistant to other IFN alpha treatments: Results of a randomized multicenter trial. [Abstract] Hepatology 1997; 26 (suppl. 2): 349A
14. Brillanti S, Foli M, di Tomaso M et al. Response to triple antiviral therapy in interferon non-responders with chronic hepatitis C. [Abstract] J Hepatol 1998; 28 (suppl. 1): 114
15. Bell H, Hellum K, Harthug S et al. Low sustained response rate of interferon plus ribavirin or interferon alone in chronic hepatitis C previously resistant to interferon. [Abstract] J Hepatol 1997; 26 (suppl. 1): 91
16. De Bac C, Pastore G, Piccinino F et al. Ribavirin and interferon retreatment of hev chronic patients non responder to interferon. [Abstract] J Hepatol 1998; 28 (suppl. 1): 123
17. Diago M. Valeros MD, Lujan M et al. Ribavirin interferon combination in patients with chronic hepatitis C non responding to interferon. [Abstract] J Hepatol 1998; 28 (suppl. 1): 196
18. Bodenheimer HC, Jr., Lindsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997; 26 (2): 473-7
19. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol 1996; 25 (5): 591-8
20. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996; 3 (5): 247-52
21. Bekkering FC, Brouwer JT, Schalm SW, Elewaut A. Hepatitis C: Viral kinetics. Hepatology 1997; 26 (6): 1691-2
22. Vento S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superin-fection in patients with chronic hepatitis C. N Engl J Med 1998; 338 (5): 286-90
23. Feray C, Gigou M, Samuel D et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993; 104 (2): 549-55
24. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in Interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23 (suppl. 2): 13-5; dis: 13-5: discussion 15-6
25. El-Zayadi A, Selim O, El Haddad S et al. Combination treatment of alpha interferon -2b (alfa IFN) and ribavirin in chronic hepatitis C genotype 4 patients resistant to interferon therapy. [Abstract] Hepatology 1995; 22 (suppl. 1)
26. Pol S, Berthelot P, Brechot C. Ribavirin-interferon vs interferon (alpha 2b-IFN) alone in non reponders to alpha-IFN in chronic hepatitis C. [Abstract] Hepatology 1996; 24 (suppl. 1): 356A
27. Benetti GP, Tagger A, Ramella G et al. Ribavirin plus interferon in the treatment of chronic hepatitis C unresponsive to alfa interferon alone. Evaluation of response in terms of ALT and quantitative viremia. [Abstract] Hepatology 1996; 24 (suppl. 1)
28. Pinar A, Salas E, Gonzales-Vilches J et al. Elevated rate of early response to high dose in IFN plus ribavirin in patients with chronic hepatitis C no responders to IFN. [Abstract] Hepatology 1997; 24 (suppl. 1): 417A
29. Milella M, Santantonio T, Pietromatera G et al. Ribavirin plus IFN vs IFN alone in the treatment of either non-responder or relapser patients with chronic hepatitis C. [Abstract] J Hepatol 1997; 26 (suppl. 1): 181
30. Vucelic B, Ostojic R, Hrstic I et al. Retreatment of chronic hepatitis C with ribavirin and interferon alpha: A study in non-responding and relapsing group of patients. [Abstract] J Hepatol 1998; 28 (suppl. 1): 197
31. Ascione A, de Luca M, Guardascione MA et al. Interferon plus ribavirin vs. interferon alone in HCV chronic liver disease non responder to a previous cycle of Interferon alone. [Abstract] J Hepatol 1998; 28 (suppl. 1): 198
32. Bellobuono A, Tempini S, Mondazzi L et al. Significant improvement of virological response after ribavirin addition to IFN in still viremic patients after the initial month of IFN therapy for chronic hepatitis C. [Abstract] J Hepatol 1998; 28 (suppl. 1): 112
33. Chemello L, Cavalletto L, Bernardinello E et al. Retreatment of chronic hepatitis C (CHC) with se quential interferon-ribavirin combination therapy. [Abstract] J Hepatol 1998; 28 (suppl. 1): 109
34. Marchi S, Ciccorossi P, Petruccelli S et al. Can interferon-ribavirin effectively treat patients who did not respond to a first conventional therapy by interferon? [Abstract] J Hepatol 1998; 26 (suppl. 1): 121
35. Tripi S, di Gaetano G, Cartabellotta F et al. Ribavirin and alpha-interferon in patients with hepatitis C not responding to interferon alone. [Abstract] J Hepatol 1998; 28 (suppl. 1): 212